Withaferin A, a Cytotoxic Steroid from Vassobia breWiflora, Induces Apoptosis in Human Head and Neck Squamous Cell Carcinoma by Samadi, Abbas K. et al.
Withaferin A, a Cytotoxic Steroid from Vassobia breWiflora, Induces Apoptosis in Human Head
and Neck Squamous Cell Carcinoma
Abbas K. Samadi,† Xiaoqin Tong,‡ Ridhwi Mukerji,† Huaping Zhang,‡ Barbara N. Timmermann,*,‡ and Mark S. Cohen*,†
Department of Surgery, School of Medicine, UniVersity of Kansas Medical Center, Kansas City, Kansas 66160, and Department of Medicinal
Chemistry, School of Pharmacy, UniVersity of Kansas, Lawrence, Kansas 66045
ReceiVed February 17, 2010
As part of a program to discover drug leads from plant biodiversity, the present investigation was undertaken to explore
the anticancer potential of compounds derived from selected Latin American plants. Bioassay-guided fractionation of
a crude extract of the aerial parts of Vassobia breViflora led to the isolation of the withanolide-type steroidal lactone
withaferin A (1). This compound was tested for antiproliferative activity against the head and neck squamous cell
carcinoma (HNSCC) cell lines, MDA1986, JMAR, UM-SCC-2, and JHU011. The inhibitory concentrations to reduce
cell viability to 50% (IC50) were determined by the MTS cytotoxicity assay, and 1 reduced cell viability with IC50
values in the range 0.5-2.2 µM. A mechanistic study showed that 1 induces apoptosis and cell death in HNSCC cells
as well as a cell-cycle shift from G0/G1 to G2/M. Cells treated with 1 exhibited inactivation of Akt and a reduction in
total Akt concentration. This investigation constitutes the first report of the antiproliferative activity of withaferin A (1)
against head and neck squamous carcinoma.
Head and neck squamous cell carcinoma (HNSCC) is the fifth
most common cancer in humans and accounts for 90% of all head
and neck malignancies, with over 780 000 new cases diagnosed
yearly worldwide.1-3 Tumors in this disease may arise from any
of the mucosal surfaces in the head and neck region including the
lips and oral cavity, tongue, nasal cavity, oropharynx, larynx, and
even the thyroid gland. Tumors typically will spread lymphatically
to cervical lymph nodes in the neck. Platinum-based therapy is the
most effective drug treatment for HNSCC; however, this treatment
may lead to significant toxicity, including ototoxicity, peripheral
neuropathy, and nephrotoxicity, accounting for up to 15% of
deaths.4 Despite advances in the diagnosis and staging of advanced
HNSCC, survival has not significantly improved in the last 30
years,3 and even with aggressive therapy, the majority of such
patients succumb to recurrent or metastatic disease.5-7 Many
patients, especially the elderly, cannot complete chemo-radiation
treatments, and a significant number of deaths are due to treatment-
related toxicity.4 Molecular-targeted therapies are being explored,
but thus far have not shown the level of benefit in HNSCC that
they produce in other forms of cancer.8 Novel drugs discovered
for this disease, especially from natural product sources, would
provide an exciting avenue for preclinical exploration in HNSCC.
Natural products have played a significant role in the discovery
and development of new anticancer agents, and they represent a
rich source of biologically active compounds. More than 79.8% of
anticancer drugs introduced from January 1981 to October 2008
were natural products, semisynthetic analogues, or synthetic
compounds based on natural-product pharmacophores.9 A library
of 200 plant extracts from Latin America was evaluated for their
cytotoxic activities against four HNSCC cell lines using the MTS
assay. The species selected for this study included one of the most
active samples from Argentina, Vassobia breViflora (Sendtn.) Hunz
(Solanaceae), which is a widespread spiny shrub with small, purple,
campanulate, glabrous flowers.10 Although significant antimicrobial
activity of the methanol extract of V. breViflora has been reported,11
there has been no chemical isolation work on this species reported
previously. Cytotoxicity-guided purification led to the isolation and
characterization of the active withanolide, withaferin A (1).
Withaferin A (1) is a part of the withanolide family of
compounds. Withanolides are naturally occurring C28-steroidal
lactones built on an intact or rearranged ergostane scaffold in which
C-22 and C-26 are appropriately oxidized to form a δ-lactone ring
on the nine-carbon side chain.12 These polyhydroxy steroids are
found in some species of the Solanaceae, and in particular, they
are abundant and structurally diverse in the genera Acnistus, Datura,
Dunalia, Lycium, Jaborosa, Physalis, and especially Withania.12,13
Withanolides are reported to possess various biological activities
in vitro and in vivo including antimicrobial,14 antineoplastic and
cytotoxic,15-21 anti- neurodegenerative,20 anti-inflammatory,22-25
and radiosensitizing,26 as well as immunomodulating, antioxidant,
antistress, cardiotonic, and insect antifeedant properties.13,26
Compound 1 was isolated earlier from Withania somnifera Dunal,
a medicinal plant used in Ayurvedic medicine for the treatment of
various ailments such as arthritis, asthma, hypertension, and
rheumatism. Its structure was elucidated in 1965 and is characterized
by an R,-unsaturated ketone in ring A, an epoxide group in ring
B, and an R,-unsaturated lactone in its side chain.12 Withaferin A
(1) has been the object of many studies and considered as a possible
agent for use in cancer therapy because of its potential antitumor
activity.13 This compound is reported to show cytotoxicity in a
variety of tumor cells including breast,15 pancreatic,17 prostate,19
lung,27 and leukemia.28
Although recent studies have demonstrated that 1 suppresses the
growth of human cancer cell lines in vitro and in vivo by causing
apoptosis,15-17 the precise mechanism, including the signals and
the pathways by which 1 induces cell death, is not fully understood.
The present study was undertaken to assess for the first time the
efficacy of 1 against several malignant head and neck squamous
cell carcinoma cell lines and to broaden the understanding of its
mechanism of action in these cells.
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Results and Discussion
The isolation process of 1 from V. breViflora was guided by
bioassay, and at each stage of purification, fractions obtained were
screened for their cytotoxic activities for JMAR, MDA1986, UM-
SCC-2, and JHU011 human HNSCC cells using the MTS assay.
The half-maximal inhibitory concentration (IC50) of the most active
fraction at each step of the isolation is summarized in Table S1
(Supporting Information). The concentration-dependent cell vi-
abilities for application of 1 to head and neck squamous cell
carcinoma are shown in Figure 1. Withaferin A reduced cell viability
of HNSCC cell lines and inhibited their growth in a concentration-
dependent manner. The IC50 values for UM-SCC-2, MDA1986,
JMAR, and JHU011 cells were 0.5, 0.8, 2.0, and 2.2 µM,
respectively. The results showed that these four cell lines are very
sensitive to treatment with compound 1.
A series of experiments evaluating cell-cycle arrest and the
apoptotic pathway were performed in order to investigate a possible
mechanism for the antiproliferative effect of 1. As shown in Figure
2, treatment of MDA1986, JMAR, UM-SCC-2, and JHU011
HNSCC cells with 3.0 µM 1 for 24 h induced a significant cell
cycle shift from the G0/G1 to the G2/M phase, from 27% to 42% in
JMAR cells (Figure 2A) and from 26% to 49% in MDA1986 cells
(Figure 2B; p < 0.01). The G2/M phase shift for UM-SCC-2 cells
was from 27% to 36% (Figure 2C) and for JHU011 cells, 25% to
34% (Figure 2D, p < 0.01). Compound 1 additionally induced S
phase arrest in JMAR, MDA1986, and UM-SCC-2 cells. Treatment
with 1 also led to an increase in sub-G0 levels in both JMAR (from
2% to 12%; p < 0.01) and MDA1986 cells (from 7% to 8%; not
significant), suggesting that JMAR cells underwent DNA fragmen-
tation, one of the early biochemical events leading to apoptosis.
In order to confirm the apoptotic action induced by 1, cells were
treated with 5.0 µM 1 for 24 h and stained with annexin
V/propidium iodide (PI). As shown in Figure 3, treatment of
HNSCC cells with 1 increased the annexin V-positive cells. Annexin
V-only staining signified the early apoptotic events, whereas dual
annexin V and PI staining indicated the late phase of apoptosis.
Treatment of JHU011 cells with 1 induced early apoptotic events
(p < 0.01) significantly from basal levels of 4.8% to 14.8%. There
was a slight increase in the late phase of apoptosis induced by 1 in
JHU011 cells, with very small PI-only staining (necrosis) observed
in JHU011 cells treated with 1. Treatment of JMAR and UM-SCC-2
cells with 1 induced significant increases in early and late apoptosis
as well as necrosis (p < 0.01). MDA1986 cells seemed less sensitive
to treatment with 1, since withaferin A did not increase annexin
V/PI staining herein.
To confirm the annexin V studies on HNSCC cells, caspase 3
activation was investigated in HNSCC (Figure 4). Treatment of
JHU011 cells induced activation of the caspase 3 enzyme, as
signified by decreased procaspase 3 levels. In addition, the caspase
3 substrate PARP was cleaved upon treatment with 1, in a
concentration-dependent manner (Figure 4). Treatment with com-
pound 1 at 1.0 µM increased PARP cleavage in JHU011 cells.
JMAR cells treated with 1 also showed a similar decreases in
procaspase 3 levels and cleavage of PARP protein in a concentra-
tion-dependent fashion. Similar results were also observed when
UM-SCC-2 cells were treated with 1. Treatment of MDA1986 cells
with withaferin A increased caspase 3 activation and PARP
cleavage. However, in line with the annexin V/PI data, a slightly
higher concentration of 1 was required to induce caspase 3
activation in MDA1986 cells (Figure 4). These results indicate that
1 induced cell-cycle arrest at the G2/M phase, and apoptosis was
confirmed by positive annexin V/PI staining as well as caspase 3
activation in the HNSCC cell lines investigated. At this point, it is
not clear whether G2/M cell cycle arrest provides conditions
conducive to caspase 3 activation.
The effect of withaferin A (1) was examined on major prosurvival
signaling pathways in HNSCC cells including PI3 kinase/Akt and
ERK1/2 MAP kinase. These data showed that 1 reduced phospho-
rylation (ser473) as well as total Akt levels in all HNSCC cells in
a concentration-dependent manner (Figure 5). Treatment of JHU011,
JMAR, and UM-SCC-2 cells with as low as 100-250 nM
concentrations of 1 reduced Akt phosphorylation (ser473). It is
interesting to note that a higher concentration of 1 was required to
inhibit Akt activity in MDA1986 cells (2.5 µM). In addition to the
effect of 1 on the reduction of phosphorylated Akt, the total Akt
levels were decreased significantly in all cell lines examined (Figure
5). These data show that 1 is a strong Akt inhibitor in HNSCC
cells. The effect of 1 was examined on ERK1/2 activation in
HNSCC cells. Withaferin A increased phosphorylation of ERK1/2
MAP kinase in JHU011, JMAR, and MDA1986 cells. Only at
higher concentrations did 1 inhibit activation of ERK1/2 in UM-
SCC-2 cells. Withaferin A had no effect on total ERK1/2 levels.
In the present study, a plant extract as well as purified 1 from V.
breViflora potently decreased cell viability of head and neck
squamous carcinoma cell lines MDA1986, JMAR, UM-SCC-2, and
JHU011 cells using the MTS assay. The IC50 concentration of this
inhibitor ranged from 0.5 to 2.2 µM among the HNSCC cell lines
used, indicating a potent antiproliferative effect. Compound 1
reduced cell viability at submicromolar concentrations in UM-
SCC-2 and MDA1986 cells. However, the head and neck squamous
cell lines used displayed differential sensitivities to 1, with UM-
SCC-2 cells demonstrating a significantly higher sensitivity to 1
than the other cell lines. Compound 1 induced a shift in cell cycle
arrest from G0/G1 arrest to the S and G2/M phase. In addition, cell
cycle arrest studies exhibited a significant increase in the subG0
fraction, indicating a likely early-DNA fragmentation event due to
treatment with 1. Moreover, flow cytometry analysis of annexin
V/PI staining in treated cells in Figure 3 showed that 1 induced a
significant level of apoptosis in these cells. Western blot analysis
studies of activation caspase 3 confirmed the annexin V/PI data.
Cell cycle arrest at mitosis seemed to be greatest in JMAR cells
with a correspondingly lower requirement for 1 for induction of
caspase 3 activation and PARP cleavage, whereas MDA1986 cells
exhibited a relatively smaller G2/M shift and showed relative
resistance to caspase 3 activation. In addition, western blotting data
demonstrated that the antiproliferative action of 1 could be in part
explained through a decrease in activation of Akt as well as the
degradation of total Akt levels. Compound 1 at submicromolar
concentrations reduced Akt phosphorylation (ser473) in JMAR,
JHU011, and UM-SCC-2 cells, whereas 1 at slightly higher than
1.0 µM was required for inhibition of Akt phosphorylation in
MDA1986 cells. Further study is required to elucidate the upstream
effect of 1 in the PI3 kinase/Akt pathway as well as downstream
events that may induce apoptosis upon Akt inhibition in HNSCC
Figure 1. Withaferin A (1) is an antiproliferative agent for the
JHU011, JMAR, MDA1986, and UM-SCC-2 head and neck
squamous cell lines. The MTS assay was used to study the effect
of 1 on cell viability of head and neck squamous carcinoma cells.
All experiments were performed in triplicate for each concentration.
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cells. In addition, Akt may phosphorylate and inhibit caspase
activation, and this may include initiator caspases (for example,
caspase-2, -8, -9, and -10) which in turn, proteolytically cleave and
activate effector (executioner) caspases (for example, caspase-3,
-6, and -7).29 Therefore, HNSCC cells (for example MDA1986)
that are relatively resistant to withaferin A (1)-mediated Akt
inhibition may therefore require higher levels of 1 to inhibit Akt
and in turn activate caspases.
In conclusion, this is the first report to date of the presence of
withaferin A in Vassobia breViflora, and this species has been
demonstrated as a new source for the production of 1. Extracts, as
well as pure 1, reduced cell viability in all four head and neck
squamous carcinoma cell lines in vitro. This mechanism of action
is in part a result of G2/M cell cycle arrest and induction of apoptosis
in HNSCC cells. Compound 1 inhibited activation of Akt and
reduced total Akt levels. Additional studies will be required to
evaluate the potential of application of the active compound 1 for
future anticancer drug development in head and neck squamous
carcinoma.
Experimental Section
General Experimental Procedures. HPLC was conducted on an
Agilent Technologies 1200 series system. IR data were obtained using
a Thermo Nicolet Avatar 360 FT-IR instrument. NMR spectra were
recorded on either a Bruker DRX-400 with a qnp probe or a Bruder
AV-500 with a cryoprobe. 1H and 13C spectra were recorded using the
residual protonated signal in the CDCl3 solvent (δH 7.24) or the central
peak of the CDCl3 triplet (δC 77.00) as the internal standard. High-
resolution mass spectrometry data were collected on a LCT Premier
time-of-flight mass spectrometer (Waters Corp., Milford, MA). Normal-
phase TLC was performed on Sorbent Technologies Silica G TLC plates
Figure 2. Compound 1 induced G2/M cell cycle arrest in HNSCC cells. JMAR (A) MDA1986 (B), UM-SCC-2 (C), and JHU011 (D) cells
were treated with DMSO or 3.0 µM 1. Cells treated with vehicle (DMSO) were primarily at the G0/G1 phase, while cells treated with
compound 1 showed shifts from the G0/G1 to the S and G2/M phases.
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(200 µm, w/UV 254) using the solvent system DCM-EtOAc-MeOH
(1:8:1), and reversed-phase TLC was performed on Sorbent Technolo-
gies C18 TLC plates (150 µm, w/UV 254) using H2O-MeOH (1:1).
Spots were visualized using UV light (254 nm) and spraying with
vanillin-sulfuric acid reagent.
Plant Material. Aerial parts of V. breViflora were collected by R.
Fortunato and A. Cabral along highway RN 86, 2 km northeast of
Primavera, Department Patino, Province of Formosa, Argentina (lat.
25°14′0′′ S, long. 57°57′0′′ W) in November 1999. A voucher specimen
(No. ARP 612) prepared by R. Fortunato was deposited in the
Herbarium (BAB) of the Institute of Biological Resources, National
Institute of Agricultural Technology (INTA), Castelar, Buenos Aires,
Argentina. Intellectual Property Rights Agreements for plant collections
and interdisciplinary research were executed between the collaborating
institutions in the U.S. and Argentina.
Extraction and Isolation. Dried, ground biomass (100 g) was
extracted at room temperature with CH2Cl2-MeOH (50:50) three times.
The concentrated extract (9.8 g) was dissolved in MeOH-H2O (10:
90) followed by partition with n-hexane, EtOAc, and n-butanol. The
EtOAc extract (2.65 g) was subjected to silica gel column chromatog-
raphy (32-60 µm, 5 × 60 cm) and eluted with gradient mixtures of
CH2Cl2-MeOH (100:0, 98:2, 95:5, 93:7, 90:10, 80:20, 50:50, and
0:100), in order of increasing polarity. A total of 182 fractions were
collected, and fractions 49-54 (830.3 mg; CH2Cl2-MeOH, 93:7) were
combined and further purified by normal-phase SPE (20 g; 60 mL)
using a step gradient of CH2Cl2-MeOH mixtures (90:10, 85:15, 80:
20, 75:25, 70:30, 65:35, 60:40, 50:50, and 0:100). Among nine collected
fractions, 50 mg of withaferin A (1) was obtained in the most active
fraction, 5 (CH2Cl2-MeOH 70:30). The identity of withaferin A (1;
Figure 3. Withaferin A (1) induced apoptosis in head and neck squamous cell carcinoma (HNSCC) cells. HNSCC cells were treated with
5.0 µM 1 for 24 h and then harvested and stained with annexin V and propidium iodide followed by analysis by flow cytometry. All
experiments were performed in triplicate. Treatment with 1 exhibited an increase in annexin V and PI staining that indicated early as well
as late apoptotic events. JMAR cells treated with 1 showed significant necrosis.
Figure 4. Caspase 3 was activated in head and neck squamous
cell carcinoma cells treated with withaferin A (1). HNSCC cells
was treated with different concentrations of 1 for 24 h. Levels of
pro-caspase 3 (inactive form) were examined with the antibody
against uncleaved caspase 3. In addition, activation of caspase 3
was examined with levels of the uncleaved and cleaved caspase 3
substrate, PARP. Compound 1 induced caspase 3 activation in all
HNSCC cell lines in a concentration-dependent manner.
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94.8% purity by HPLC) was determined by a combination of 1D and
2D NMR, HR-MS, IR, and X-ray diffraction data, which were in
accordance with values reported in the literature,30,31 and cochromatog-
raphy done with an authentic sample purchased from Chromadex
(Irvine, CA; see Supporting Information). Withaferin A (1) was soluble
in chloroform but not in ethyl acetate. Colorless, block-shape crystals
of 1 were obtained from a mixture of chloroform and ethyl acetate
(ratio 1:2). The purity of the final 1 was determined to be 95% by
HPLC analysis according to a method previously reported.13
Bioassay Materials. Culture media, fetal bovine serum (FBS),
penicillin G, streptomycin, MEM-nonessential amino acids, ribonuclease
A, and propidium iodide (PI) were obtained from Sigma-Aldrich (St.
Louis, MO). MEM-vitamin solution was purchased from Life Tech-
nologies, Inc. (Grand Island, NY). MTS reagents were obtained from
Promega Co (Madison, WI). Annexin V-FITC was from BD Bioscience
(Bedford, MA). Primary antibodies against total ERK and -actin and
secondary antibodies against mouse and rabbit antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Primary
antibodies against phospho-Akt, total-Akt, phospho-ERK, caspase 3,
and PARP were obtained from Cell Signaling Technologies (Beverly,
MA). BCA protein assay reagents were obtained from Pierce (Rockford,
IL). Protease inhibitor mixture set II was obtained from Calbiochem
(San Diego, CA).
Cell Culture and Media. The invasive oral squamous carcinoma
cell lines JMAR and MDA1986 were a gift from Dr. Jeffrey Myers
(University of Texas, M.D. Anderson Cancer Center; Houston, TX).
The head and neck squamous carcinoma cell line UM-SCC-2 was a
gift from Dr. Scott Weed (University of West Virginia, Morgantown,
WV). They were grown in DMEM supplemented with 10% FBS,
sodium pyruvate, nonessential amino acids, L-glutamine, a 2-fold MEM-
vitamin solution, and 1% penicillin/streptomycin. The laryngeal squa-
mous carcinoma cell line JHU-011 was kindly donated by Dr. Joseph
Califano (Johns Hopkins University, Baltimore, MD). This was cultured
in RPMI-1640, supplemented with 10% FBS and 1% penicillin/
streptomycin. Adherent monolayer cultures were maintained on plastic
plates and incubated at 37 °C with 5% CO2.
Cytotoxicity Assay. The experiment was performed by the MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H tetrazolium] assay according to the manufacturer’s
instructions. In brief, 1 was dissolved in dimethyl sulfoxide (DMSO)
and then diluted with culture media to prepare serial concentrations,
while the controls received only DMSO (<0.1%, v/v). The cells were
seeded in 96-well microtiter plates (2 × 103 cells/well) in 100 µL of
growth medium. After incubation for 24 h, varying levels of plant
extracts or 1 were added to each well and incubated for 72 h. Then, 20
µL of MTS solution was added. After 3 h of incubation at 37 °C (5%
CO2), absorbance was measured at 490 nm with a microplate reader.
Percent viability was calculated as a fraction of the negative control
(culture medium only), with data plotted as a function of percent cell
viability versus concentration of 1. The half-maximal inhibitory
concentration (IC50) was obtained from the MTS viability curves using
GraphPad Prism 5. All studies were performed in triplicate. In parallel
with wells of the test samples, negative control wells with predetermined
cell numbers were used to normalize the absorbance readings and to
provide internal confirmation that the assay was linear over the range
of absorbance and cell numbers measured. Cisplatin at various
concentrations was used as a positive control in the MTS cytotoxicity
assay.
Western Blot Analysis. After treatment cells were lysed (0.5%
Nonidet P-40, 100 mM, 10 mM Tris (pH 7.5), 1:500 protease inhibitor
mixture set II, 1 mM NaF, and 1 mM sodium orthovanadate) and lysates
were placed on ice for 20 min. Clear lysates were obtained by
centrifugation (14000g for 20 min). Equal amounts of protein were
separated by SDS-PAGE and electrotransferred onto a Hybond nitrocel-
lulose membrane (Amersham). The membranes were blocked and
probed with the appropriate dilution of primary antibody overnight at
4 °C. The blots were washed three times in PBS-Tween-20 for 10
min and then incubated in horseradish peroxidase-conjugated secondary
antibody in PBS-Tween-20 at room temperature for 1 h. After washing
in PBS-Tween-20, the proteins were visualized by enhanced chemi-
luminescence reagent (Amersham) and captured on Kodak XAR-5 film
(Eastman Kodak, Rochester, NY). Where indicated, the blots were
reprobed with antibody against -actin to ensure equal loading and
transfer of proteins.
Cell-Cycle Arrest Study. After treatment, cells were trypsinized
and 1 × 106 cells were washed with 0.9% NaCl and fixed with 70%
cold ethanol in 0.9% NaCl for 30 min at room temperature. After
centrifugation (700g; 5 min) cells were stained with propidium iodide
(50 µg/mL in PBS) for 30 min. Then, cells were treated with DNase-
free RNase (1 mg/mL) for 30 min and analyzed by a Becton Dickinson
LSRII flow cytometer.
Apoptosis Analysis. In order to evaluate the induction of apoptosis,
cells were costained with annexin V/PI and analyzed using flow
cytometry. An analysis of phosphatidylserine on the outer leaflet of
apoptotic cell membranes was performed using annexin V-FITC and
PI to distinguish between apoptotic and necrotic cells. After treatment,
cells (1 × 106 cells/mL) were stained with annexin-V and PI according
to the manufacturer’s instruction (BD Pharmingen, San Diego, CA).
To each tube was added 400 µL of 1× annexin binding buffer, and
Figure 5. Compound 1 modulated prosurvival signal transduction pathway. HNSCC cells were treated with increasing concentrations of 1
for 24 h. Total levels of phospho-Akt, total Akt, phospho-ERK, and total ERK2 were determined by western blotting. Antibody against
-actin was used as a protein loading control. Compound 1 reduced Akt activation as well as total cellular Akt, while ERK1/2 was activated
in JHU011, JMAR, and MDA1986 cells and ERK1/2 activity decreased in UM-SCC-2 cells at a high concentration of 1. Total ERK levels
remained unchanged when cells were treated with compound 1.
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stained cells were analyzed using a flow cytometer (BD LSRII; Becton
Dickinson, San Diego, CA).
Statistical Methods. Statistical analysis was carried out using the
Student t test and Fisher’s exact test. Means were calculated from three
independent experiments.
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